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AbstrAct
Objective to comprehensively assess evidence on the 
measurement properties of the minimal disease activity 
(MDa) criteria, a composite measure of the state of disease 
activity in psoriatic arthritis (Psa).
Methods a targeted literature review was conducted to 
identify studies that informed the validity and/or ability 
of the MDa to detect change among patients known to 
have experienced a change in clinical status. the search 
was conducted using MeDline and embase databases 
(published as of October 2017). Pertinent articles provided 
by investigators and identified from select conference 
proceedings were also evaluated.
Results a total of 20 publications met the inclusion 
criteria. the MDa criteria were consistently associated 
with other indicators of disease activity/severity. the 
ability of the MDa criteria to detect change was supported 
in randomised controlled trials (n=10), with a greater 
percentage of patients randomised to active treatments 
achieving MDa relative to patients in comparator arms. 
long-term observational studies (n=2) provided additional 
support for the ability of the MDa to detect within-subject 
change in the real-world settings.
Conclusion evidence supports the MDa as a valid 
measure of disease activity in Psa that can detect 
between-group and within-subject change. the MDa 
is a comprehensive measure and clinically meaningful 
endpoint to assess the impact of interventions on Psa 
disease activity.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic 
immune-mediated inflammatory musculo-
skeletal disease.1 As an immune-mediated 
disease with heterogeneous manifestations, 
it typically presents with skin and musculo-
skeletal symptoms, including skin and nail 
psoriasis, peripheral arthritis, enthesitis, 
dactylitis and spondylitis.2 3 PsA may result in 
permanent joint damage leading to reduced 
health-related quality of life (HRQoL) and 
physical function.2–4 Associated comorbidi-
ties include cardiovascular disease,1 3 5 meta-
bolic syndrome,3 5 obesity,3 5 6 depression,1 3 5 
anxiety,1 3 5 and may include conditions, such 
as inflammatory bowel disease3 5 and uveitis.5 7 
Prevalence among the general population has 
been reported to range from 1 to 420 cases per 
100 000 globally; and 250 cases per 100 000 in 
the USA.8 Among patients with psoriasis, the 
prevalence varies from 6% to 41% depending 
on study methodology3 and the annual inci-
dence has been reported to be approximately 
3% in patients followed prospectively.9 Diag-
nosis and assessment of PsA is complex as a 
result of heterogeneity in disease presenta-
tion and the presentation of symptoms that 
evolve over the course of the disease.10 11 
Patients can experience periods of disease 
flares, minimal disease activity (MDA) and 
remission.12
The ultimate treatment goal for PsA is clin-
ical remission or inactive disease.13 14 Since, 
for many patients, complete remission may 
Key messages
What is already known about this subject?
 ► Psoriatic arthritis (Psa) is an immune-mediated dis-
ease with heterogeneous manifestations. currently, 
available measures do not capture all relevant as-
pects of the Psa disease activity, thus emphasising 
the need for a disease assessment tool that is tar-
geted and comprehensive, which can assess multi-
ple domains of the disease.
What does this study add?
 ► this is a targeted literature review of the available 
evidence that supports utility, validity and relevance 
of the minimal disease activity (MDa) as a measure 
of disease activity in Psa.
How might this impact on clinical practice?
 ► this targeted literature review provides supportive 
evidence for MDa criteria as a targeted, practical 
and easy to interpret measure that can be used in 
both clinical practice and randomised controlled tri-
als to assess disease activity in Psa.
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Table 1 Relationship between MDA status and CRP
Author (year) Study description Sample size MDA subgroup
CRP score,
median (IQR); mean 
(SD)
Coates and Helliwell 
(2010)22
Post hoc analysis of two 
RCTs to validate the MDA 
criteria
157 MDA (n=63) Median, 0.4 mg/dL 
(0.4–0.6)
Non-MDA (n=94) Median, 0.5 mg/dL 
(0.4–1.3)
P value 0.019
Queiro et al (2017)25 Cross-sectional 
observational study
277 MDA (n=133) Mean, 2.8 mg/L (3.9)
Non-MDA (n=144) Mean, 4.7 mg/L (8.2)
P value <0.05
CRP, C reactive protein; MDA, minimal disease activity; Non-MDA, patients not achieving MDA; RCT, randomised controlled trial.
be difficult to attain, MDA, low or very low disease activity 
(VLDA) have been proposed as alternative goals. Given 
the multiple domains of PsA, a composite endpoint that 
captures all relevant aspects of the disease is critical to 
the overall interpretation of research study results and 
patient management. The PsA core domain set recom-
mended by the Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis (GRAPPA)/Outcome 
Measures in Rheumatology (OMERACT) for randomised 
controlled trials (RCTs) and long-term observational 
studies includes musculoskeletal disease activity, skin 
disease activity, fatigue, pain, patient global assessment 
(PtGA), physical function, HRQoL and systemic inflam-
mation (defined by acute phase reactants) as key domains 
that are important to both patients and physicians.15 The 
most common PsA endpoint for Food and Drug Admin-
istration approval of treatments is the American College 
of Rheumatology (ACR) response criteria,16 which were 
developed as an endpoint for rheumatoid arthritis RCTs. 
The ACR response criteria do not capture the distinct 
features of PsA, such as enthesitis, dactylitis, axial disease 
or skin manifestations, thus, additional instruments to 
assess these manifestations are included in RCTs, such as 
the Psoriasis Area Severity Index (PASI) and assessments 
for the presence of dactylitis and enthesopathy.17–19 
Several composite disease measures have been proposed, 
including Disease Activity in Psoriatic Arthritis (DAPSA; 
focuses solely on arthritis), Composite Psoriatic Disease 
Activity Index (CPDAI), Psoriatic Arthritis Disease Activity 
Score (PASDAS), Psoriatic Arthritis Response Criteria 
(focuses solely on arthritis) and GRAPPA Composite 
Exercise Index.20 These measures are all continuous and 
remission is generally defined as a score below a cut-off 
value.
Recognising the need for a tool to better capture 
heterogeneous disease activity among PsA patients that 
equates to a clinically meaningful indicator of disease 
status, Coates et al developed a PsA-specific, composite 
measure of disease state, the MDA criteria.21 22 The MDA 
criteria were developed consistent with OMERACT 
recommendations. In contrast to continuous measures, 
the MDA serves as an indicator of the current state of 
PsA disease.20 Patients achieve MDA if they meet five of 
seven criteria: tender joint count ≤1; swollen joint count 
≤1; PASI ≤1 or body surface area (BSA) ≤3; patient pain 
Visual Analogue Scale (VAS) ≤15; PtGA ≤20; Health 
Assessment Questionnaire (HAQ) ≤0.5 and tender 
entheseal points≤1 (21). MDA response rates have been 
assessed in longitudinal observational studies (LOSs) and 
RCTs.20 Individual components of the MDA criteria are 
well established. Of the seven individual components, five 
components are included in the ACR response criteria 
and the remaining two components (ie, PASI ≤1 or BSA 
≤3 and tender entheseal points ≤1) have been used in 
RCTs to assess the efficacy of PsA treatments. The MDA is 
gaining acceptance as a meaningful composite index that 
can be used to monitor disease activity across all PsA clin-
ical pathologies23 and has been proposed as a compre-
hensive measure for treat-to-target (T2T) approach in 
PsA.13 Recently, VLDA has become a clinically relevant 
benchmark for disease remission and has been defined 
as meeting seven of the seven MDA criteria.23
The objectives of this targeted literature review were 
to comprehensively assess evidence regarding the perfor-
mance characteristics of the MDA criteria and their utility 
as a measure of disease activity in PsA. Specifically, this 
review focused on summarising evidence of the validity 
of the MDA criteria, and the ability of the MDA criteria 
to detect between-groups and within-patient differences. 




A targeted literature review was conducted to identify the 
existing evidence for the measurement properties of the 
MDA. Publications were identified using MEDLINE with 
PubMed Interface and Embase databases and there were 
no language or time frame restrictions for the literature 
search. The search terms used from controlled vocab-
ularies MeSH were: ‘minimal disease activity, minimal 
disease activity index, minimal disease activity measure, 
psoriatic arthritis, psoriatic arthropathy, surveys and 
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Table 2 Relationship between MDA status and measures of structural damage






subgroups Time point Subgroup Measure
Cross-sectional studies
Presence of hand 
erosions















patients with no 
progression of joint 
damage or mean (SD) 
of joint damage score
Coates et al 
(2010)26
Prospective longitudinal 
observational study to 
establish the frequency 
and predictors of MDA
















Post hoc analysis of two 
RCTs to validate the MDA 
criteria
Increase in modified 
SHS score of >0
Phase II RCT (n=63) Week 50 MDA (n=26) 96
Non-MDA (n=37) 67
P value 0.012
Week 100 MDA (n=12) 100
Non-MDA (n=25) 58
P value 0.03
Phase III RCT (n=157) Week 54 MDA (n=63) 78
Non-MDA (n=94) 57
P value 0.009
Geijer et al 
(2015)27
Prospective longitudinal 
observational study to 
evaluate the course of 
the disease and identify 
predictors of progression











Post hoc analysis of 
RCT, placebo to explore 
relationship of MDA to 
radiographic progression
Increase in SHS 
score >0
In MDA ≥3 consecutive 
visits over the course 
of the 256 week study 
(n=116)
256 weeks MDA (n=41) 35.3
Non-MDA (n=75) NR
P value 0.054
In MDA ≥4 consecutive 
visits over the course of 
the 256 week study (n=95)
256 weeks MDA (n=34) 35.8
Non-MDA (n=61) 23.2
P value 0.056
*Patients evaluated every 6–12 months.
†P value represents comparison of mean change in joint damage over the study period in MDA versus non-MDA.
‡Mean scores not reported for females; however, it was noted that the statistical comparison of joint damage for MDA versus non-MDA was not significant.
MDA, minimal disease activity; Non-MDA, patients not achieving MDA; NR, not reported; RCT, randomised controlled trial; SHS, Sharp/van der Heijde Score.
questionnaires, questionnaires and rating scales, outcome 
assessment, minimal important change,’ and combina-
tions thereof. In addition, pertinent articles provided by 
the investigators were evaluated for selection, including 
abstracts from conference proceedings from the annual 
ACR meetings and EULAR meetings. The same selection 
criteria were applied to articles identified in literature 
databases and to conference abstracts.
Publications were identified in two separate literature 
searches. The first was conducted in February 2016; this 
search was updated in October 2017.
study selection and data extraction
After an initial screen of title and abstract, potentially 
relevant full-text publications were retrieved for further 
review. Articles were included if they provided evidence 
regarding the development or measurement properties 
of the MDA. Publications were excluded if they met any 
of the following criteria: reported only the rationale for 
developing the MDA; examined the relationship between 
baseline variables associated with achievement of MDA 
but did not inform measurement properties; clinical 
effectiveness studies with no comparator group; and 
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Table 3 Relationship between MDA status and PRO measures
Author (year) Study description Sample size Time point Criterion variable MDA subgroup Score
Cross-sectional studies Mean (SD)
Queiro et al (2017)25 Cross-sectional 
observational study
277 — PsAID total score* MDA 3.3 (3.1)
Non-MDA 7.1 (5.2)
P value <0.001
Longitudinal studies Change from baseline
Mease et al (2017a)31 Post hoc analysis of 
RCT to validate MDA 
criteria and HRQoL 
outcomes
135 Week 24 SF-36 PCS MDA 13.3
Non-MDA 3.5
P value <0.001
SF-36 MCS MDA 5.0
Non-MDA 0.3
P value <0.01
DLQI total MDA −5.8
Non-MDA −2.8
P value 0.01
FACIT Fatigue MDA 8.6
Non-MDA 1.3
P value 0.001
Coates et al (2016)30 Post hoc analysis of 
RCT to validate MDA 
criteria and HRQoL 
outcomes
397 Week 24 SF-36 PCS MDA 9.0
Non-MDA 4.6
P value <0.001






FACIT fatigue MDA 9.0
Non-MDA 4.9
P value <0.001
PsA QoL MDA −5.2
Non-MDA −3.3
P value <0.001
Week 52 SF-36 PCS MDA 9.9
Non-MDA 4.6
P value <0.001






FACIT fatigue MDA 9.5
Non-MDA 5.4
P value <0.001
PsA QoL MDA −5.7
Non-MDA −3.4
P value <0.001
*PsAID total score ranges from 0 (best health status) to 10 (worst health status).
DLQI, Dermatology Life Quality Index; FACIT, Functional Assessment of Chronic Illness Therapy; HRQoL, health-related quality of life;MCS, Mental Component Score; MDA, minimal 
disease activity; Non-MDA, patients not achieving MDA;PCS, Physical Component Score; PROs, patient-reported outcomes; PsAID, Psoriatic Arthritis Impact of Disease; PsA QoL, 
psoriatic arthritis quality of life; RCT, randomised controlled trial; SF-36, Short Form 36 Health Survey.
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Table 4 Kappa’s agreement between MDA and alternate disease activity criteria
Author (year) Study description
Sample 
size Time point Criterion κ
Measures of disease activity
Coates and Helliwell 
(2016)32
Prospective longitudinal observational study of 
GRACE dataset collected from 32 countries to 
explore the relationship between MDA and low 
disease activity cutoffs
503 Week 24 PASDAS 0.73
CPDAI-4 0.75
CPDAI-3 0.75
Rahman et al (2017)33 Prospective longitudinal observational study 223 12 months DAS28 (<2.6) 0.65
DAS28 deep remission (1.98) 0.60
DAPSA remission (≤4) 0.65
Lubrano et al (2015)34 Prospective longitudinal observational study to 
compare PtGA with MDA and other outcome 
measures.
124 4 months PtGA 0.73
8 months PtGA 0.72
12 months PtGA 0.73
Categorical measures
Coates and Helliwell 
(2016)32
Described above 503 Week 24 MDA-joints* 0.86
MDA-phys† 0.48
*BSA, and not the PASI, was the cut-off used for the skin domain.
†MDA as judged by the treating physician=do you think this patient is in an MDA state? (yes/no).
BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; DAPSA, Disease Activity in Psoriatic Arthritis; DAS28, Disease Activity Score using 28 joints; GRACE, 
Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Disease Exercise; MDA, minimal disease activity; PASDAS, Psoriatic Arthritis Disease Activity Score; 
PASI, Psoriasis Area and Severity Index; PtGA, patient global assessment.
conference abstracts except those reporting results of 
phase III RCTs.
All studies were reviewed by an independent reviewer 
and the following data were extracted: author and year of 
publication; study characteristics, including study design 
and type (including but not limited to RCTs and post 
hoc analysis of RCTs; LOS and post hoc analyses of LOS; 
study years; sample size; study population characteris-
tics; experimental treatment and findings related to the 
measurement properties of the MDA.
To evaluate the validity of the MDA, reported clin-
ical endpoints were assessed and descriptive data and 
statistical comparisons were extracted for patients in 
MDA versus non-MDA for the following variables, where 
available:
1. C reactive protein (CRP)—patients in MDA were ex-
pected to have lower CRP levels, indicative of overall 
lower levels of inflammation.
2. Structural damage—patients in MDA were expected 
to have less evidence of joint damage by radiographs 
and/or clinical report.
3. Patient-reported outcomes (PROs)—patients in MDA 
were expected to report better HRQoL, physical and 
mental function, and lower levels of fatigue relative to 
patients not in MDA.
To further evaluate the validity of the MDA, Kappa’s 
agreement statistics were summarised between MDA and 
alternate measures of disease activity, where available. 
The kappa values associated with the level of agreement 
are as follows: none (κ=0–0.2); minimal (κ=0.21–0.39); 
weak (κ=0.40–0.59); moderate (κ=0.60–0.79); strong 
(κ=0.80–0.90) and almost perfect (κ>0.90).24
To determine the ability of the MDA to detect changes 
in clinical studies, descriptive data and statistical compari-
sons were extracted for treatment and comparator groups 
in RCTs and LOS. Study drugs with known efficacy were 
assessed for the percentage of patients taking the active 
treatment relative to the comparator arm in achieving 
MDA; a greater percentage receiving active treatment 
were expected to achieve MDA compared with those 
receiving placebo.
ResulTs
search results and study characteristics
The combined literature reviews identified 20 relevant 
publications that provided information on the meas-
urement properties of the MDA and these were selected 
for data extraction. One publication was a conference 
abstract presenting results of a phase III trial and the 
remainder of the publications were journal articles. 
Of these 20 publications, nine articles reported results 
from observational studies and the remaining reported 
results from RCTs. All publications that met eligibility 
criteria are summarised in online supplementary table 
S1.
Validity
MDa status and crP
Two studies assessed the relationship between MDA and 
CRP, a marker of systemic inflammation (table 1).
Coates and Helliwell evaluated the ability of the MDA 
to differentiate among patients based on CRP and found 
an association between CRP levels and achievement of 
MDA.22 In this analysis, CRP levels were significantly 
lower in patients who achieved MDA than in those who 
did not (p=0.019). Results of a cross-sectional observa-
tional study among Spanish PsA patients published by 
Queiro et al were consistent with the above findings.25 
Queiro et al reported that CRP scores were significantly 
lower in patients in MDA than in those who were not 
(p<0.05).
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Table 5 Ability to detect change in RCTs
Author (year) Study description
Sample size
Time point Primary comparison
Percentage 
of patients 
achieving MDATotal PsA only
Coates and Helliwell 
(2010)22
Post hoc analysis of two RCTs 
to validate the MDA criteria
Phase 2=63 63 Week 16 Infliximab 48
Placebo 3
P value <0.0001
Phase 3=157 157 Week 24 Infliximab 52
Placebo* 21
P value <0.001
Coates et al (2016)30 Post hoc analysis of phase 
III RCT
397 397 Week 16 Secukinumab 150 mg 23
Secukinumab 300 mg 28
Placebo 10
Week 52 Secukinumab 150 mg 33
Secukinumab 300 mg 35
Gladman et al 
(2017)41
Phase III RCT, placebo 394 394 Week 12 Tofacitinib 5 mg 22.9
Tofacitinib 10 mg 21.2
Placebo 14.5
P value NR
Week 28 Tofacitinib 5 mg 23.7
Tofacitinib 10 mg 23.5
Placebo/tofacitinib 5 mg 18.2
Placebo/tofacitinib 10 mg 29.2
P value NR
Kavanaugh et al 
(2016)28
Post hoc analysis of 
RCT, placebo to explore 
relationship of MDA to 
radiographic progression
395 395 Week 14 Golimumab 23.5
Placebo 1
P value <0.0001
Week 24 Golimumab 28.1
Placebo 7.7
P value <0.0001
Week 52 Golimumab 42.4
Placebo 30.2
P value <0.0001















Mease et al (2017)31 Phase III RCT
(week 24—active treatment 
end of study; weeks 48–144—
open-label extension)
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Author (year) Study description
Sample size
Time point Primary comparison
Percentage 
of patients 
achieving MDATotal PsA only
Mease et al (2014)42 Post hoc analysis of RCT data 
to explore relationship with 
MDA
409 409 Week 24 Certolizumab pegol




Mease et al (2015)43 Post hoc analysis of RCT data 
to explore relationship with 
MDA
409 409 Week 48 (imputation) Certolizumab pegol
(combined patients 
randomised to active treatment 
at baseline)
38.8
Week 96 (imputation) Certolizumab pegol
(combined patients 
randomised to active treatment 
at baseline)
41.0
Mease et al (2017)19 Post hoc analysis of RCT, 
placebo to investigate 
achievement of MDA












422 Week 12 Tofacitinib










(5 mg and 10 mg)
31.0; 34.0
P value NR
Nash et al (2017)45 Post hoc analysis of RCT, 
placebo to investigate 
achievement of MDA
363 363 Week 24 Ixekizumab




*Forty-seven patients in the placebo group entered the early escape arm at week 16 and received infliximab.
MDA, minimal disease activity; NR, not reported; PsA, psoriatic arthritis; RCT, randomised controlled trial.
Table 5 Continued
MDa status and measures of structural damage
Queiro et al reported the relationship between MDA and 
presence of radiographic erosions in the hands and feet 
in a cross-sectional study (table 2).25
Patients in MDA were less likely to have evidence 
of hand erosions compared with those who were not 
(p<0.05); however, there were no significant differences 
among patients when evaluating presence of erosions in 
the feet.
Four longitudinal studies reported the progression of 
structural damage over time in patients achieving MDA 
and in those who did not (table 2).22 26–28 Across these 
studies, patients in MDA had lower rates of structural 
damage progression; these differences were statistically 
significant in three of four studies. In a post hoc anal-
ysis of phase II and phase III RCTs, Coates and Helli-
well reported that patients in MDA were less likely to 
exhibit structural damage progression.22 In the phase 
II RCT, patients achieving MDA were significantly less 
likely to have increases >0 in the modified Sharp/van 
der Heijde Scores (SHS) at week 50 (p=0.012) and 
week 100 (p=0.03) compared with patients not in MDA. 
In the phase III trial, patients in MDA at week 54 were 
also less likely to have evidence of structural damage 
progression (p=0.009). Kavanaugh et al conducted a 
post hoc analysis of a phase III RCT that reported the 
relationship between achievement of MDA over consec-
utive study visits (≥3 visits and ≥4 visits) and increases in 
SHS >0 over the 256-week treatment period.28 Results 
for both subgroups (≥3 and ≥4) were in the anticipated 
direction; however, they were not statistically signif-
icant (p=0.054 and p=0.056, respectively). Coates et 
al assessed the rate of structural damage progression 
over a 5-year prospective LOS among patients in MDA 
and those who were not.26 The average follow-up was 
34 months and patients in MDA were significantly less 
likely to have structural damage progression (p<0.001). 
The rate of structural damage progression by the 
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Table 6 Ability to detect change in prospective LOS
Author (year) Study description
Sample 




Rahman et al 
(2017)33
Biological treatment registry to 
examine MDA rate over time






Perrotta et al 
(2016)36
Prospective longitudinal study 
to examine MDA status with the 
indices of disease activity and to 









†Article reports the percentage of patients achieving MDA status at 12 months was significantly different from baseline but does not report p 
value.
LOS, longitudinal observational studies; MDA, minimal disease activity.
Wassenberg score over a 256-week follow-up period in 
a prospective LOS has been reported by Geijer et al for 
a cohort of PsA patients in Sweden and was found to be 
significantly lower among patients in MDA (p=0.042).27
MDa status and PrOs
Three studies examined the relationship between MDA 
status and PROs and are summarised in table 3.
The relationship between MDA status and physical and 
psychological function measured by the PsA Impact of 
Disease Questionnaire (PsAID) was evaluated by Queiro 
and colleagues in an observational, cross-sectional 
study.25 The PsAID measures the physical and psycho-
logical impact of disease on patients’ lives.29 Results indi-
cated that patients in MDA reported significantly lower 
impacts of disease than patients who were not in MDA 
across all domains and total PsAID scores (p<0.001).25 
Eighty-eight (66.7%) MDA patients reported a PsAID 
score <4 compared with 34 (37.4%) non-MDA patients 
(p<0.0001).
Two studies reported the relationship between changes 
over time in PROs and MDA. In both, patients in MDA 
reported significantly more improvements across all 
PROs assessing HRQOL and fatigue: Short Form 36 
Health Survey, Dermatology Life Quality Index (DLQI), 
Functional Assessment of Chronic Illness Therapy-Fa-
tigue, and PsA quality of life.30 31 Additional data from 
these studies are summarised in table 3.
AgReeMenT beTWeen MdA And AlTeRnATIVe MeAsuRes Of 
dIseAse ACTIVITy
Several publications evaluated the relationship between 
MDA and other overall disease activity indicators (such 
as the PASDAS, CPDAI, Disease Activity Score (DAS), 
DAPSA and PtGA) by calculating Kappa’s (κ) coefficients 
(table 4).
Coates and Helliwell reported moderate agreement 
(κ=0.73–0.75) with three alternative definitions of 
treatment responses: PASDAS, CPDAI-4 and CPDAI-3.32 
Agreement was also strong for MDA joints (κ=0.86) but 
weak for MDA-phys (κ=0.48). The relationship between 
MDA and disease activity reported by the patient 
(measured as a patient-reported overall indicator of 
disease activity) was also evaluated. The κ coefficient 
between MDA and patients’ rating of whether they were 
in a minimal disease state was 0.30.
Rahman et al reported a moderate κ agreement between 
achievement of MDA and three additional disease activity 
measures, including DAS using 28 joints (DAS28, <2.6), 
DAS28 deep remission (DAS28 <1.98) and DAPSA remis-
sion (≤4).33 Lubrano et al reported moderate agreement 
between MDA and a single item of the MDA, PtGA 
(κ=0.72–0.73).34 As part of the same LOS, Lubrano et al 
then evaluated the sensitivity and specificity in differen-
tiating patients rated by their physician as being in MDA 
(<10 mm on a 100 mm VAS) versus a higher disease state 
(≥10); sensitivity was 0.90 (0.74–0.98) and specificity 0.69 
(0.57–0.79).35
Ability to detect change
Ten RCTs that provide evidence on the between-patient 
treatment effects of the MDA were identified (table 5) 
and indicated that those who received treatment with 
a targeted immunomodulator were significantly more 
likely to achieve MDA than those who received placebo.
Two prospective LOS provide evidence on the with-
in-patient treatment effects (table 6). In these studies, 
over 1 year of treatment with a disease-modifying anti-
rheumatic drug resulted in an increasing proportion of 
patients achieving MDA.33 36
Very low disease activity
One study reported both MDA and VLDA from a post hoc 
analysis of a 24-week RCT that compared adalimumab to 
placebo. Mease et al reported that of 66 patients receiving 
adalimumab, 24 (36.4%) achieved MDA and 10 (15.4%) 
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VLDA. In contrast, of 69 patients in the placebo group, 
only four (5.7%) and zero (0%), respectively, achieved 
MDA and VLDA.31
dIsCussIOn
This targeted literature review assessed the current 
evidence of the performance characteristics of the MDA 
criteria and their utility as a measure of disease activity in 
PsA. The validity and relevance of the MDA as a measure 
of disease activity was strongly supported based on the 
strength and consistent association between MDA status 
and each of these domains.
Across studies, MDA responses were in the anticipated 
direction of other disease indicators, such as CRP, struc-
tural damage progression, patient-reported HRQoL, pain 
and fatigue and global assessments of disease activity. The 
consistency reported in the literature provides strong 
evidence that MDA is a valid indicator of disease activity 
in PsA.
MDA is frequently reported in RCTs that examine the 
efficacy of treatments for PsA. Across all RCTs included 
in this literature review, a greater proportion of patients 
assigned active treatment achieved MDA versus placebo/
control groups. A growing body of evidence also supports 
the ability of the MDA criteria to detect within-patient 
changes over time, providing further support for its use 
in LOS and RCTs.
Recent T2T recommendations have highlighted the 
aspiration for remission or VLDA, but for many patients, 
low disease activity or MDA may be an appropriate 
treatment target.13 The MDA criteria have been recom-
mended by both the T2T international task force13 and 
the GRAPPA/OMERACT group to assess treatment 
target goals.37 While MDA does not measure disease 
activity, it is a feasible target of treatment assessing 
multiple domains of the disease. The MDA criteria can 
be used in all patients with PsA regardless of their disease 
pattern, whereas other measures do not reflect disease 
activity across all subgroups of PsA. It gives a target that 
is appropriate for both polyarticular and oligoarticular 
patients. In some other measures (eg, ACR response 
and DAPSA) of disease activity the focus is primarily on 
articular inflammation,13 which may not reflect the full 
range of disease activity in some PsA patients. PASDAS 
is another disease activity measure that covers multiple 
domains, but it does not include skin and is complex to 
use in clinical practice at present.
Measures like MDA that generally focuses on multiple 
domains of the disease can evade inclusion of patients 
having an active domain, which may otherwise be cate-
gorised as cohort with remission or low disease activity. 
van Mens et al reported that prevalence of skin disease 
was higher in patients with PsA who had DAPSA remis-
sion compared with other measures. Given that DAPSA 
is an unidimensional measure, it particularly focuses 
only on peripheral joint disease. Hence, it does not 
address important manifestations of PsA, where MDA, a 
multidimensional measure, addresses all of them.38 In a 
recently published study, Coates et al concluded that in 
comparison with DAPSA, definitions of VLDA and MDA 
are more stringent in evaluating PsA.39
The MDA criteria offer a targeted and easy to inter-
pret disease assessment, and have been incorporated into 
both clinical practice and trial settings.38 MDA is based on 
commonly performed clinical examinations, with some 
additional, easy to administer PROs (ie, PtGA, pain VAS 
and HAQ) and skin evaluations (ie, PASI or BSA), and 
determining MDA requires minimal training and time 
for the required assessments. PRO measures are increas-
ingly being incorporated into clinical practice settings, 
which will further enable assessment of MDA.40
There are several limitations to this targeted literature 
review that warrant consideration when interpreting the 
results presented in this manuscript. This review sought 
to qualitatively characterise information on the measure-
ment properties of the MDA. Although a thorough 
search strategy was employed to capture all pertinent 
publications, the potential exists that not all relevant 
publications were identified. Further investigation into 
this is needed to evaluate stability of the score among 
patients with stable disease activity. Furthermore, each of 
the studies included in this review used different meth-
odological approaches to study design (cross-sectional 
vs longitudinal), population analysed, study duration 
and endpoints evaluated, thereby limiting the ability to 
collectively summarise findings.
This literature review provides a detailed evaluation 
of the measurement properties of the MDA and shows 
strong evidence for the validity of the MDA as a measure 
of PsA disease activity and its sensitivity to detect changes 
with treatment. Substantial data support its use as a prac-
tical, comprehensive and clinically meaningful endpoint 
for clinicians to assess the impact of specific treatment 
interventions on PsA disease activity.
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